MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Glaukos Corp

Closed

SectorHealthcare

120.43 6.31

Overview

Share price change

24h

Current

Min

118.28

Max

121.36

Key metrics

By Trading Economics

Income

3.4M

-16M

Sales

9.4M

134M

EPS

-0.16

Profit margin

-12.155

Employees

995

EBITDA

8.1M

-570K

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+11.42% upside

Dividends

By Dow Jones

Next Earnings

17 Feb 2026

Market Stats

By TradingEconomics

Market Cap

2B

6.4B

Previous open

114.12

Previous close

120.43

News Sentiment

By Acuity

36%

64%

111 / 361 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Glaukos Corp Chart

Past performance is not a reliable indicator of future results.

Related News

16 Jan 2026, 23:29 UTC

Hot Stocks

Stocks to Watch: Atossa Therapeutics, Union Pacific

16 Jan 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 Jan 2026, 22:43 UTC

Acquisitions, Mergers, Takeovers

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 Jan 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 Jan 2026, 21:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

16 Jan 2026, 21:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Auto & Transport Roundup: Market Talk

16 Jan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 Jan 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

16 Jan 2026, 21:48 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 Jan 2026, 21:41 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 Jan 2026, 21:38 UTC

Acquisitions, Mergers, Takeovers

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 Jan 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 Jan 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 Jan 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 Jan 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 Jan 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 Jan 2026, 20:44 UTC

Earnings

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 Jan 2026, 20:42 UTC

Market Talk

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 Jan 2026, 20:28 UTC

Market Talk

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 Jan 2026, 19:12 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 Jan 2026, 18:53 UTC

Market Talk

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 Jan 2026, 18:41 UTC

Market Talk

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 Jan 2026, 18:31 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 Jan 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

16 Jan 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 Jan 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

16 Jan 2026, 17:03 UTC

Market Talk

Global Equities Roundup: Market Talk

16 Jan 2026, 17:03 UTC

Market Talk

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16 Jan 2026, 16:32 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16 Jan 2026, 16:20 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer Comparison

Price change

Glaukos Corp Forecast

Price Target

By TipRanks

11.42% upside

12 Months Forecast

Average 127.55 USD  11.42%

High 165 USD

Low 72 USD

Based on 14 Wall Street analysts offering 12 month price targets forGlaukos Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

13

Buy

0

Hold

1

Sell

Technical Score

By Trading Central

87.61 / 93Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

111 / 361 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
help-icon Live chat